Innovation is a vital part of drug development, and key to improved market access. Whilst generics are often the mainstay of the market, there are opportunities to create truly innovative therapeutics in other areas, including cell and gene therapies and biologics, as well as novel delivery systems and drug/device combinations. Small companies and university spinoffs could be vital in making the most of innovation, but they will need support and advice if they are to gain global market access.

In this edition, Quintiles' experts share their insight into the challenges that both small and large companies face around gaining global market access - particularly in large markets like the US, and markets with specific requirements such as hospital negotiations in Germany or cancer treatment within the UK NHS.